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Human immunodeficiency virus (HIV)-1 is mainly
transmitted mucosally during sexual intercourse.
We therefore evaluated the protective efficacy of
a vaccine active at mucosal sites. Macaca mulatta
monkeys were immunized via both the intramuscular
and intranasal routes with an HIV-1 vaccine made of
gp41-subunit antigens grafted on virosomes, a safe
delivery carrier approved in humans with self-
adjuvant properties. Six months after 13 vaginal
challenges with simian-HIV (SHIV)-SF162P3, four
out of five vaccinated animals remained virus-nega-
tive, and the fifth was only transiently infected.
None of the five animals seroconverted to p27gag-
SIV. In contrast, all 6 placebo-vaccinated animals
became infected and seroconverted. All protected
animals showed gp41-specific vaginal IgAs with
HIV-1 transcytosis-blocking properties and vaginal
IgGs with neutralizing and/or antibody-dependent
cellular-cytotoxicity activities. In contrast, plasma
IgGs totally lacked virus-neutralizing activity. The
protection observed challenges the paradigm
whereby circulating antiviral antibodies are required
for protection against HIV-1 infection and may serve
in designing a human vaccine against HIV-1-AIDS.
INTRODUCTION
Human immunodeficiency virus (HIV)-1 is mainly acquired at the
mucosal site during sexual intercourse. Previous vaccine strate-gies against HIV-1 were aimed at inducing circulating neutral-
izing IgG antibodies or cytotoxic T cells (CTLs). Both strategies
have repeatedly failed to elicit protection against HIV-1 infection
in vivo (Tatsis et al., 2009; Rerks-Ngarm et al., 2009; Buchbinder
et al., 2008). An alternative strategy could be the development of
a vaccine that elicits amucosal immune response and blocks the
entry of the virus at mucosal sites before primary infection takes
place locally in the lamina propria.
The advantage of mucosal antibodies as a potential protection
mechanism is supported by studies on individuals who are
HIV-1-exposed but remain persistently seronegative (HEPS).
In these individuals of both genders, one correlate of protection
is the presence of gp41-specific IgAs in the blood and genital
secretions, which display HIV-1-neutralizing activity and HIV-1
transcytosis-blocking activity (Devito et al., 2000a; Miyazawa
et al., 2009; Tudor et al., 2009). Transcytosis is one of the mech-
anisms of entry of the virus into mucosal tissues (Bomsel 1997;
Bomsel et al., 1998). Gp41-specific IgAs also block in vitro infec-
tion of mucosal target cells (Devito et al., 2000b; Miyazawa et al.,
2009; Tudor et al., 2009), thereby preventing entry into and trans-
cytosis across epithelial cells (Devito et al., 2000a; Bomsel et al.,
1998; Alfsen et al., 2001) and blocking access of the virus to the
lamina propria (Hladik and McElrath, 2008). Although IgGs may
interfere with viral infection in tissues underlying mucosal
epithelia and secondary lymphoid tissues, mucosal IgAs, which
have a known compartmentalized distribution and repertoire, are
thought to best protect mucosal surfaces.
Gp41 is the most conserved envelope subunit of HIV-1 with
very few potential glycosylation sites as opposed to the surface
envelope subunit gp120, whose neutralizing epitopes are widely
masked by glycans. Gp41 and especially its hydrophobic
membrane proximal external region (MPER), whose structure is
strictly dependent on the lipidic environment provided by the
viral membrane (Coutant et al., 2008; Sun et al., 2008), isImmunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc. 269
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Gp41 Vaccine Protects from Mucosal SHIV Infectiontargeted by the broadly neutralizing IgGs 2F5 and 4E10. These
IgGs provide sterilizing immunity against mucosal HIV-1 chal-
lenge, as shown by passive transfer studies, even at a low or
undetectable concentration of serum antibodies at the time of
protection (Hessell et al., 2010). Mucosal IgAs in HEPS individ-
uals also target the extended MPER and exhibit both transcyto-
sis-blocking and infection-neutralizing activity (Devito et al.,
2000a, 2000b; Miyazawa et al., 2009; Tudor et al., 2009).
As reviewed by Montero et al. (2008), several immunogens
based on peptides and proteins containing the MPERwere eval-
uated in various animal models by monitoring blood IgGs and
CTL. HIV-1-neutralizing IgG antibodies could not be elicited
in vivo and specific CTL responses, despite an in vitro activity,
lackedprotective activity in vivo. In these studies, the immunogen
design did not properly take into account the 3D structure of viral
antigens thatmost likely differs greatly from its native structure on
the virus. Furthermore, the route of immunization was not adap-
ted to induce a humoral mucosal response, either in terms of
compartmentalization or epitope specificity (Brandtzaeg 2009).
In this study, we used market-approved virosomes (Moser
et al., 2007; Herzog et al., 2009) as a carrier—in use for humans
for more than 10 years—to deliver two distinct HIV-1 gp41
antigens: a recombinant, truncated, trimeric gp41 (rgp41)
antigen (Delcroix-Geneˆte et al., 2006) and the P1 peptide (Alfsen
andBomsel, 2002;Mage´rus-Chatinet et al., 2007; Yu et al., 2008;
Coutant et al., 2008). P1 corresponds to the extended MPER
region of gp41 and includes the binding site to the mucosal
receptor galactosyl-ceramide that is present on epithelial and
dendritic cells (Alfsen and Bomsel, 2002; Mage´rus-Chatinet
et al., 2007; Yu et al., 2008; Coutant et al., 2008). We designed
the antigens by removing from gp41 the immuno-dominant
epitopes (Delcroix-Geneˆte et al., 2006) that are known to be
nonneutralizing. Therefore, the current design of the gp41-
derived antigens allows for focusing the immune response on
protective HIV-1 envelope epitopes. Immunization of nonhuman
primate females by both the intramuscular (i.m.) and intranasal
(i.n.) routes with both gp41-derived virosome-bound antigens
elicited full protection against repeated SHIV-SF162P3 vaginal
challenges, whereas immunization by the i.m. route alone eli-
cited protection in just 50% of the animals. The protected
animals showed gp41-specific cervicovaginal IgAs and IgGs
with transcytosis-blocking and antiviral activities, but showed
no neutralizing IgG activity in their serum.
RESULTS
Antigen Design and Vaccine Strategy
The HIV-1 vaccine strategy of this study was designed to focus
on the mucosal humoral immune responses against conserved
gp41-derived antigens, the P1 peptide (Alfsen and Bomsel,
2002), and a newly engineered trimeric recombinant gp41
(rgp41) (Delcroix-Geneˆte et al., 2006) from the X4 tropic, clade
B HXB2 isolate of HIV-1. This new rgp41 (residues 540–664) is
a stable trimer, produced in E. coli, that has several conserved
key epitopes of gp41 (Serres, 2001; Delcroix-Geneˆte et al.,
2006), a deletion of the conserved immunodominant cluster I
region, and additional point mutations introduced to break up
homology with interleukin-2 (IL-2) and other human proteins.
These later deletions were introduced to prevent a potential270 Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc.autoimmune response upon vaccination (Serres, 2001). In addi-
tion, rgp41 contains the caveolin binding site-1 (CBD1) shown to
induce HIV-1 neutralizing antibodies (Hovanessian et al., 2004)
and the QARILAV neutralizing epitope, the latter being targeted
by IgAs from HEPS individuals (Miyazawa et al., 2009). The P1
peptide corresponds to the gp41 MPER and contains the galac-
tosyl ceramide-binding site and the 2F5 and 4E10 epitopes. Both
the rgp41 antigen and the P1 peptide were linked by the
C terminus to phosphatidylethanolamine, allowing their easy
insertion into the lipid membrane of virosomes. In this lipidic
context, HIV-1 antigens can fold as in situ in the viral membrane
(Coutant et al., 2008; Sun et al., 2008).
The virosome vector is a nonreplicative virus-like particle
derived from influenza that is formed by a lipid bilayered vesicle
into which molecules of the influenza virus hemagglutinin (HA)
and neuraminidase (NA) are inserted, thereby allowing efficient
targeting of antigen-presenting cells. Virosomes have intrinsic
adjuvant properties, elicit blood and mucosal antibodies (data
not shown and Moser et al., 2007), and are licensed for use in
human vaccines (Moser et al., 2007). Importantly, pre-existing
antibodies against the influenza hemagglutinin (HA) were not re-
ported to prevent revaccination with virosomes in human, in
contrast to thesituationwith someviral vectors (Tatsisetal., 2009).
Female Macaca mulatta of Chinese origin were used to eval-
uate the in vivo protective efficacy of the gp41-based virosome
vaccine against a virulent SHIV vaginal challenge. The mucosal
antibody response is highly compartmentalized, at the level of
both the induction (immunization route) and the effector sites,
in terms of antibody repertoire and specificity (reviewed in
Brandtzaeg, 2009). Therefore, the animals were vaccinated by
either the intramuscular (i.m.) route of immunization alone, or
by a combined intramuscular plus intranasal route (i.m.+i.n.).
Three groups of Chinese rhesus monkeys received four
administrations of vaccine at weeks 0, 7, 15, and 23 (Figure 1A).
Six animals (control group 1) received the virosome carrier alone.
Six animals (group 2) were vaccinated four times by the i.m. route
only, whereas six animals (group 3) received two injections by
the i.m. route followed by two booster injections by the i.n. route.
Each vaccine dose contained 40 mg of P1 and 40 mg of rgp41.
One of the animals in group 3 unfortunately died of an unrelated
cause before immunization was completed.
Gp41 Virosome Immunization Protects FemaleMonkeys
from Repeated SHIV-SF162P3 Vaginal Challenges
Onemonth after the last vaccination, all animals were challenged
intravaginally thirteen separate times, biweekly for the first four
weeks and then once a week for the remaining five weeks,
with a low dose (20–30 TCID50) of the heterologous SHIV-
SF162P3 (clade B, R5 tropism).
Viremia was investigated blindly for up to 208 days after the
initial challenge (Figures 1B–1D). Starting after the ninth chal-
lenge, the six animals in control group 1 all became infected (Fig-
ure 1B), with viral loads peaking at 106 to107 copies/mL, as ex-
pected (Harouse et al., 2001). In group 2 (i.m. immunization),
three of the animals were infected with peaks of viremia at 105
to 107 copies/mL, whereas two animals showed only transient
peaks of viremia of %250 copies/mL and one consistently had
no detectable viremia (Figure 1C). In contrast, only one of the
animals in Group 3 (i.m.+i.n.) showed a low transient viral load
Figure 1. Immunization and Challenge
As experimental schedule (A), Female Macacca mulatta were immunized four times at week (W) 0, 7, 15, and 23 with a mixture of two distinct virosome formu-
lations corresponding to virosme-P1 and virosome-rgp41 in a total volume of 100 ml per dose. Group 1 received the empty virosome carrier as placebo, whereas
groups 2 and 3 received 40 mg of P1 and 40 mg of rgp41 grafted onto virosomes. All animals from groups 1, 2, and 3 were immunized by the i.m route at W0 and
W7. Afterward, groups 1 and 2 continued to receive i.m. immunizations at week 15 and 23, whereas animals from group 3 received two i.n. immunizations with
50 ml of the vaccine in each nostril administered with a specific spray device (Accuspray, BD). Blood, vaginal, and rectal washes were collected from each animal
at week4 and 0 for preimmune samples and 1 week after each vaccination event for immune samples (weeks 1, 8, 16, and 24). One month after the last immu-
nization, animals from groups 1 (B), 2 (C), and 3 (D) were challenged 13 times with 20–30 TCID50 of SHIV-SF162P3 intravaginally (indicated by black arrows).
Blood samples were drawn over 6 months and analyzed at indicated time points for plasma viral load determination. The horizontal black line indicates the lower
detection limit of RNA copies/mL.
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undetectable levels a week later, and all the other animals in
the group had very low or undetectable amounts of viremia
(Figure 1D).
For confirming the absence of infection in the viremia-negative
animals, the presence of serum IgG against SIV p27gag antigen
was investigated at day 100. As expected, the protected group 3
(i.m.+i.n.) animals and the viremia negative animals in group 2
(i.m. only) did not develop p27gag-specific serum IgGs. In
contrast, all the infected animals from group 1 and group 2
showed a strong IgG response against p27gag SIV (Figure 2A).
Furthermore, p27-specific IgAs were detected in the vaginal
compartment of almost all viremia-positive animals, whereas
the signal for specific mucosal IgG was very weak (Figure 2B).
These results were confirmed with serum samples taken
3 months later (not shown).
The absence of detectable p27-specific blood IgG and
mucosal IgA in animals from groups 2 and 3 with undetectableviremia suggests that in these animals, local exposure to the
p27 antigens during the 13 consecutive challenges with SHIV-
SF162P3 was not sufficient to elicit the induction of gag-specific
antibodies in detectable quantities. Furthermore, the fact that
animal 3.3 from the i.m.+i.n.-vaccinated group did not serocon-
vert in spite of its transient viremia suggests that if infected, this
animal rapidly resolved its infection.
Protection Is Not Associated with a Specific
MHC Class I Haplotype
Specific MHC class I antigens (including Mamu-A*01, -A*02,
-B*08, and -B*17) have been associated with SIV control (Lof-
fredo et al., 2009). In the present study, all animals were negative
for Mamu-A*01 and Mamu-A*02 (data not shown). There were
two animals in group 2 (2.4 and 2.6) that were Mamu-B*08
positive, and one animal per group (1.1, 2.1, and 3.3) was posi-
tive for Mamu-B*17. These genetic traits did not apparently
affect the results of the study.Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc. 271
Figure 2. p27 Serology at Day 100 after the
First Challenge with Heterologous SHIV-
SF162P3
Sera (A), and cervico-vaginal secretions (CVS, B)
from preimmune animals (day 0) and at day 100
after the first challenge (100) were analyzed for
p27gag SIV-specific antibody content by immuno-
blotting.
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and Mucosal Antibody Responses
Because the virosomes used in the present study are not
designed for triggering a CTL response (Amacker et al., 2005;
Wilschut 2009), we limited our investigation to the humoral
response. In the serum at week 24, the rgp41- and P1-specific
IgG and IgA responses were observed in almost all animals in
group 2 (i.m. only), whereas in group 3 (i.m.+i.n.), the response
was not always detectable (Table 1). At the mucosal level at
week 24, gp41- and P1-specific IgAs were detected in cervico-
vaginal secretions (CVSs) and rectal secretions (RSs) of most
immunized and protected animals. Regarding mucosal IgGs,
only rgp41-specific IgGs, but not P1-specific IgGs, could be
detected (not shown). A sizeable immune response required
four immunizations as indicated by analyses of the samples at
weeks 8 and 16 (Tables S1 and S2 available online). Overall,
the mucosal immune response detected here may have been
underestimated because detection of mucosal antibodies is
always limited by the minute quantity of fluid that can be
collected at each sampling time and by the dilution factor.
Furthermore, the ELISA test used here only measured antibodies
specific for linear and lipid-independent epitopes as we have
shown earlier (Coutant et al., 2008).
Taken together, these results indicate that the vaccine formu-
lation was immunogenic, inducing both gp41-specific IgAs and
IgGs in the systemic and mucosal compartments.
HIV-1-Blocking Antibodies Develop in the Mucosal
Compartment, but Not in Serum
The functional inhibitory potential of the serum andmucosal anti-
bodies in the vaccinated animals was investigated in an HIV-1
epithelial cell transcytosis assay (Bomsel 1997; Alfsen et al.,
2001). HIV-1-neutralizing activity was also studied with CD4+
T cells as target. The potential protective role of IgGs using not
only their variable regions—that recognize the antigen—but
also their Fc region was also evaluated in antibody-dependent
cell cytotoxicity (ADCC) assay.
None of the sera of the vaccinated and protected animals at
a dilution of 1/250 exhibited measurable neutralizing activity in
any of the classical neutralization tests (data not shown),
including inhibition of HIV-1 infection with TZM-bl cells and
various recombinant viruses expressing primary envelopes,272 Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc.namely SF162, qh0692, and du172,
SOS assays or CD4+ T cell assays
with clade B R5-tropic HIV-1 JR-CSF
(data not shown). Furthermore, ADCC
mediated by serum could not be de-tected with P1 or recombinant gp160-coated CD4+ T cell targets
(data not shown).
In contrast to serum, cervico-vaginal secretions (CVSs)
exhibited various highly marked HIV-1 neutralization activities
(Table 2, Figure 3). Table 2 shows that mucosal antibodies from
CVS from the five animals in group 3 at a 6-fold dilution
(corresponding to 0.2–15 mg of total antibodies/mL) could block
HIV-1 transcytosis of a primary clade B, R5-tropic virus by
85%–100%. No blocking activity was detected in CVS samples
from the placebo group. When tested against a primary clade
C virus strain (Table 2), four out of five CVS samples could block
transcytosis by more than 75%. These results demonstrate that
the i.m.+i.n. immunization strategy could induce mucosal anti-
bodies with in vitro cross-clade transcytosis-inhibition activity.
Transcytosis-blocking activity in CVS samples from group 2
animals (i.m. only) was >90% for clade B and >60% for clade C
viruses in two of the three uninfected animals but negligible in
the infectedanimals.Pairwisegroupcomparisonsshowedasignif-
icantly higher transcytosis-blocking activity in CVS from group 3,
as compared to group 1 (placebo) for both clade B (p = 0.0054)
(Figure 3A) and clade C (p = 0.0097) viruses (Figure 3B). Statisti-
cally significant differences, although lower, were also detectable
between groups 2 (i.m.) and 1 (placebo) for both viral clades (p =
0.016 and 0.04, respectively).
To determine which antibody isotype contained in CVS was
actually involved in the prevention of HIV-1 transcytosis (Bomsel
1997), we depleted samples of IgA content and retested them.
Figure 4 clearly demonstrates that no inhibition of transcytosis
could be observed in the CVS samples depleted of IgAs. In
contrast, IgG-depletion of the same samples had no effect on
their transcytosis-blocking capacity. These results strongly
suggest that the IgA fraction harbored the inhibitory activity,
whereas the IgGs had no substantial role in preventing HIV-1
transcytosis in this model.
As opposed to sera that contain very high, specific antibody
concentrations upon vaccination, mucosal secretions generally
contain a 100- to 1000-fold lower concentration of antibodies,
which make their evaluation difficult in neutralization assays.
CVS from group 3 generated limited neutralization activity for
three out of the five monkeys when tested for neutralizing of
human CD4+ T cell infection by HIV-1, a standard neutralization
assay (Table 2, Figure 3E), although statistically significantly
Table 1. Evaluation of Antibodies toward the P1 and rgp41 Antigens in Each Animal
Sample Serum CVS RS
Monkey Group 1:CT 2:i.m. 3:i.m.+i.n. 1:CT 2:i.m. 3:i.m.+i.n. 1:CT 2:i.m. 3:i.m.+i.n.
P1
IgA 0/6 5/6 4/5 0/6 5/6 5/5 0/6 5/6 2/5
IgG 0/6 6/6 3/5 0/6 6/6 2/5 0/6 0/6 0/5
rgp41
IgA 0/6 6/6 5/5 0/6 6/6 4/5 0/6 5/6 4/5
IgG 0/6 6/6 3/5 0/6 6/6 5/5 0/6 0/6 0/5
Systemic and mucosal responses to P1 and rgp41 in femaleMacaca mulattamonkeys after completion of the vaccination procedure with virosome-
rgp41 and virosome-P1 (week 24 compared to week 0) in sera and CVS were analyzed by antigen-specific ELISA. For mucosal samples, results were
calculated as the percent specific IgA or IgG of the total IgA or IgG in each sample, respectively, so as to account for the variation of total Ig between
each mucosal sample. Samples showing a specific signal at least twice above the background were considered positive. Shown is the number of
animals with specific IgAs or IgGs over the total number of animals in each group.
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Gp41 Vaccine Protects from Mucosal SHIV Infectiondifferent from group 1 (placebo) (p = 0.0097, Figure 3E). In
contrast, no biologically relevant neutralizing activity was found
in CVS samples from groups 1 and 2.
Table 2 further shows that CVS IgGs from all group 3 animals
exhibited substantial ADCC activity, regardless of the IgGs
specificity for either P1 or rgp41, although P1-specific ADCC
was always stronger. An ADCC activity was also detected for
CVS IgGs from group 2 animals that were viremia negative,
although with an overall lower ADCC titer. In contrast, IgGs
from the placebo group (group 1) totally lacked ADCC activity.
Pairwise group comparisons showed clearly a significantly
higher P1-specific ADCC in CVS from group 3 (i.m.+i.n.) as
compared to group 1 (placebo) (p = 0.0055) (Figure 3C), whereas
the difference for rgp41-specific ADCC was less substantial (p =
0.028) (Figure 3D).
These sets of results were confirmed when comparing either
viremia positive (including animals with low viremia blips fewer
than 300 RNA copies/ml) versus viremia negative animals
(Figures S1A–S1D) or when comparing persistently infected
versus protected animals (Figures S2A–S2D).
Finally, for all animals taken together, a strong highly signifi-
cant inverse correlation was observed between clade B and
clade C HIV-1 transcytosis-blocking activity in CVS and peak
acute viremia (Figures 5A and 5B) (r = 0.832; p < 0.0001 and
r = 0.850; p < 0.0001, respectively). P1-specific ADCC also
inversely correlated significantly with peak acute viremia (r =
0.682; p = 0.0036) (Figure 5C), but no correlation was found
between viral loads and gp41-specific ADCC (Figure 5D) or
neutralization activities (Figure 5E).
In summary, these experiments showed altogether that
i.m.+i.n. immunization with P1- and rgp41-coupled virosomes
fully protected female rhesus macaque from 13 repeated vaginal
challenges with SHIV-SF162P3, whereas placebo-vaccinated
animal all become viremic and seroconverted to p27. The pro-
tected animals showed gp41-specific cervicovaginal IgAs and
IgGs with antiviral and transcytosis-blocking activities but
showed no neutralizing IgG activity in their serum.
DISCUSSION
Because HIV-1 is mainly a sexually transmitted infection, we de-
signed a vaccine strategy to protect the initial sites of viral entry,especially the rectum and female genital tract, by inducing
a mucosal humoral immune response that hopefully would be
able to prevent the establishment of early viral infection at these
mucosal sites.
Although there is recurrent interest in gp41, and especially its
MPER moiety, to serve as a vaccine antigen, little information
exists on the ability of gp41-specific antibodies to act as protec-
tive antiviral antibodies in vivo. However, intravenously adminis-
tered MPER-specific monoclonal IgGs obtained from HIV+
patients were recently shown to protect male rhesus monkeys
from a single high-dose rectal SHIV challenge (Hessell et al.,
2010), supporting MPER as a potent vaccine candidate. Yet, in
that study neither the mucosal titers nor the in vitro functions
of the gp41-specific antibodies were evaluated. The best
evidence for an antiviral role at mucosal sites of gp41-specific
HIV-1 blocking IgAs, including MPER-specific ones, is offered
by HEPS individuals for which such mucosal IgA antibodies
are one of the correlates of protection (Miyazawa et al., 2009;
Tudor et al., 2009).
How to raise such HIV-1 gp41 antibodies with antiviral activi-
ties by vaccination remains an open question (Montero et al.,
2008). The gp41 antigen described here was split into a rgp41
(Delcroix-Geneˆte et al., 2006) and peptide P1 (Alfsen and Bom-
sel, 2002) engineered to adopt a 3D structure close to the struc-
ture adopted on the virus in close proximity to the lipid bilayer
(Coutant et al., 2008), provided here by the virosome vaccine
vector. Immunodominant, although nonneutralizing, gp41
epitopes were deleted so that inducing a useless humoral
response was avoided, thereby refocusing the humoral
response on the less immunogenic key epitopes of the antigen.
Studies comparing humoral immunity at mucosal surfaces
with serum immune responses have repeatedly shown a separa-
tion between secretory and systemic immune responses.
Immunization at mucous membranes resulted in high titers of
protective antibodies at mucosal effector sites, whereas the
serum humoral response showed a lower neutralization titer (re-
viewed in Macpherson et al., 2008). Specific combinations of
chemokine receptors and adhesion molecules mediate B cell
homing to mucosal and peripheral tissues. Accordingly, nasal
vaccination leads to development of a humoral response locally
but also in the female genital tract and in the large intestine (Mac-
pherson et al., 2008). In contrast, i.m. immunization induces bothImmunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc. 273
Table 2. Transcytosis-Blocking, ADCC, and HIV-1 Neutralization
Activities in Cervico-Vaginal Secretions, after the Last
Immunization with P1- and rgp41-Virosomes
Transcytosis












1.1 0 0 0 0 0
1.3 5 0 0 0 0
1.4 0 0 0 0 0
1.5 0 0 0 0 0
1.6 0 12 0 0 0
i.m.
2.1 28.2 65 27 9 6
2.2 3.1 4.5 3 3 6
2.3 2.0 0.75 3 3 6
2.4 89.8 12 3 0 6
2.5 96.0 71 27 3 0
i.m.+i.n.
3.1 96 99 27 9 6
3.3 94 73 3 3 0
3.4 96 85 3 0 6
3.5 100 42 27 9 0
3.6 85 78 27 9 18
Positive Controls
2F5 IgG 98 N.A. 800 pg/ml N.A. 15 mg/mL
98.6 IgG N.A. N.A. N.A. 32 pg/ml N.A.
For transcytosis blockade, preimmune (week 0) and immune (after the
fourth immunization) (week 24) CVS at 1:6 dilutions from group 1
(placebo), group 2 (i.m.), and group 3 (i.m.+i.n.) animals were tested as
described in Experimental Procedures and in the legend of Figure 3.
For ADCC, preimmune and immune (after the fourth immunization) CVS
at serial dilutions from 1:3 to 1:27 from groups 1, 2, and 3 were tested
comparatively for P1- or rgp41-specific ADCC activity as indicated in
Experimental Procedures. Results, obtained from at least two indepen-
dent experiments, are expressed as ADCC titer as defined in Experi-
mental Procedures. For neutralization, preimmune and immune (after
the fourth immunization) CVS (1:6 dilution) from groups 1 and 3 were
compared for their neutralizing activity against infection of CD4+ T cells
with JR-CSF R5 tropic HIV-1 as indicated in Experimental Procedures.
Results are expressed as the highest inhibitory CVS dilution resulting in
50% specific neutralization (IC50). Results were obtained from at least
two independent experiments. Specific neutralization is defined by the
neutralization observed in presence of immune CVS related to that
observed in presence of preimmune CVS (week 24 % week 0).
Immunity
Gp41 Vaccine Protects from Mucosal SHIV Infectiona systemic and a vaginal humoral response (Vajdy et al., 2004;
Vajdy 2006; Barnett et al., 2008). The combination of i.m. and
i.n. immunizations in the rhesus monkey model results in
substantially enhanced anti-HIV-1 plasma and vaginal anti-
bodies (Vajdy et al., 2004; Vajdy 2006; Barnett et al., 2008).
Accordingly, we compared in this study the gp41-specific
antibody response elicited with the sole i.m route or the
combined i.m.+i.n. routes of vaccination. The two procedures
induced a clear-cut differential degree of antibody antiviral activ-274 Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc.ities as measured both in vitro and upon virulent mucosal heter-
ologous challenge in vivo. Hence, after the mucosal challenge,
we observed a full protection in the i.m.+i.n.-immunized group
only, as compared to 50% protection in the i.m.-immunized
group. In the combined i.m.+i.n. immunization procedure, the
i.m. step might have primed the serum antibody response
(IgG), whereas the i.n. step would have boosted the mucosal
responses with antiviral activities (Zhou et al., 2009).
The six-month vaccination period allowed for affinity matura-
tion of the mucosal antibodies (data not shown) that character-
izes neutralizing antibodies (Wu et al., 2010). Such maturation
affinity was also observed in our initial vaccination experiments
with the virosome-P1 alone.
In vivo protection was investigated by repeated heterologous
challenges by the vaginal route with physiological doses (20
and 30 TCID50) of infectious SHIV-SF162P3. This strategy was
designed to be close to natural HIV-1 transmission, using the
genital route of transmission and a dose of infectious virus close
to that present in unprotected intercourse, even though this viral
dose is 10 times greater than the dose found in semen in sero-
positive men (Hessell et al., 2009). The antigens in the vaccine
were derived from HXB2, an X4, clade B, HIV-1 strain, whereas
challenge of the vaccinated animals was done with the R5, clade
B, SHIV-SF162P3 virus strain. Most previous studies only tested
homologous challenges (reviewed in Demberg and Robert-Gur-
off, 2009).
SHIV, although slightly attenuated as compared to SIV, was
chosen as the challenge virus for the following reasons: the
HIV-1 envelope glycoprotein is essential in the initial steps of
HIV-1 infection, but SIV and HIV-1 envelopes differ largely in
amino acid sequence, length, and structure; as a result, antibody
specific for HIV-1 gp41 cannot recognize the corresponding
region on the SIV envelope and SIV is not sensitive to an immune
response targeting HIV-1 envelope. Therefore, for mimicking the
situation in the human and evaluating the initial steps of HIV-1
infection that are exclusively dependent on HIV-envelope-medi-
ated fusion with target cells, one needs to use a virus expressing
an HIV-1 envelope. Rather, SIV is appropriate to evaluate the
development of the infection and its prevention. Given that the
vaccine described here targeted specifically HIV-1 envelope
subunit gp41, the use of SIV was prohibited.
Our results indicate that combining the i.m.+i.n. routes (group
3) offers the best protection to the animals, with undetectable
viral load for six months in five out of five animals—except for
a transient and low peak of viremia that lasted 1 week in one of
the monkeys—as compared to 50% protection for animals
vaccinated by the i.m. route only (group 2). Because of the low
sensitivity of the viremia assay (threshold at 200 copies/mL), it
remains possible that the protected animals were actually in-
fected to a very low degree. However, none of the i.m.+i.n. vacci-
nated animals had detectable blood or mucosal antibodies
against SIV p27gag antigen at 3 and 6 months after challenge,
confirming the absence of an established infection. The same
was true for the three protected monkeys in group 2.
The most likely correlate of protection in the vaccinated
animals appears to be contributed by the antiviral activity of
mucosal gp41-specific IgGs and IgAs. Circulating antibodies
were devoid of anti-HIV activity, whether in neutralization tests,
in transcytosis-inhibition tests, or in ADCC tests. Besides,
Figure 3. HIV-1 Transcytosis-Blocking, ADCC, and
Neutralization Activities in Cervico-Vaginal Secre-
tions after Immunization with P1 and rgp41 Viro-
somes
For transcytosis-blockade, preimmune (week 0) and
immune (after the fourth immunization: week 24) CVS at
1:6 dilution from group 1 (placebo), group 2 (i.m.), and
group 3 (i.m.+i.n.) animals were preincubated with PBMCs
infected with primary HIV-1 clade B 93BR029 (A) or clade
C 92BR025 (B) prior to addition to the luminal side of polar-
ized epithelial cell monolayers. Transcytosis inhibition is
defined by the ratio of neutralization observed in presence
of immune CVS related to that observed in presence of
preimmune CVS (week 24 % week 0). Values are the
mean (±SEM) of at least two independent experiments.
For ADCC, preimmune and immune (after the fourth
immunization: week 24) CVS at serial dilutions from 1:3
to 1:27 were tested comparatively for P1- (C) and rgp41-
(D) specific ADCC activity as described in Experimental
Procedures. Results are expressed as ADCC-specific
lysis. Values are the mean (±SEM) of at least two indepen-
dent experiments. For neutralization, preimmune and
immune (after the fourth immunization: week 24) CVS
(1:6 dilution) from groups 1, 2, and 3 were compared for
their neutralizing activity against infection of human
CD4+ T cells by JR-CSF R5 tropic HIV-1 as described in
Experimental Procedures (E). Results are expressed as
specific neutralization defined as the ratio of neutralization
observed in presence of immune CVS related to that
observed in presence of preimmune CVS (week 24 %
week 0). Values are the mean (±SEM) of at least two inde-
pendent experiments. For all functional tests, statistical
analyses were performed first by the Kruskal-Walis test;
pairwise comparisons were performed by the Mann-Whit-
ney U-test, the p values are presented in each panel. KW
statistic = 11.212, p = 0.0037 (A); KW statistic = 10.562, p =
0.0051 (B); KW statistic = 11.677, p = 0.0029 (C), KW
statistic = 6.881, p = 0.0320 (D); KW statistic = 8.856,
p = 0.0119 (E).
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virosome surface, a role for vaccine-induced CTLs is unlikely
(Amacker et al., 2005; Kammer et al., 2007) (Wilschut 2009),
although it remains a possibility that a (weak) CTL response
was induced. We and others have previously shown that CTL
responses can be triggered by the virosome strategy when
specific CTL epitopes from the membrane bound antigens
are encapsulated inside the virosomes (Amacker et al., 2005;
Kammer et al., 2007) (Moser et al., 2007) (Wilschut 2009).
However, this was not the case in the present study. Therefore,
possible cell-mediated immune responses were not investigated
in the present study.
It should be noted that noCTLepitopes have beendescribed in
the P1 subunit used in the present study and only two potential—
but weak ones (Currier et al., 2002; Novitsky et al., 2002)—are
present on the rgp41 subunit (see the LANL HIV immunology
database), with the most potent one being deleted by our
immuno-refocusing strategy. Interestingly, a protective CTLImmunity 34, 269response has recently been suggested to
provide robust control of mucosal infection after
a repeated mucosal virulent SIV challenge in 4
out of 12 rhesus monkeys vaccinated witha SIV protein-encoding replicative vaccine (Hansen et al.,
2009). In the protected (although infected) animals, the
protective CTL response observed was directed to Rev, Nef,
and Tat. Yet no response to Env—including gp41—was reported.
Antibodies contained in the cervico-vaginal secretions of
the i.m.+i.n.-vaccinated animals were capable of inhibiting
by >80% the in vitro transcytosis of primary HIV-1 viruses from
clades B and C, suggesting cross-clade recognition. This is
particularly interesting, given that the tested HIV-1 clade C virus
does not have the 2F5 and 4E10 motifs in its gp41 sequence.
This suggests that other functional epitopes and/or 3D epitope
(s) might be shared between the clade B and C gp41 molecules,
despite the absence of linear epitope identity. HIV-1-blocking
IgAs specific for such cross-clade epitopes in HIV-1 envelope
(Devito et al., 2002) and more specifically in P1 are detected in
HEPS individuals (Tudor et al., 2009) and were also induced in
monkeys upon intramuscular or mucosal immunization with viro-
some-P1 alone.–280, February 25, 2011 ª2011 Elsevier Inc. 275
Figure 4. HIV-1 Transcytosis-Blocking Activities in Cervico-Vaginal
Secretions from Group 3 after IgA or IgG Depletion
CVS from group 3 (white bars) were IgA- (black bars) or IgG- (gray bars)
immuno-depleted prior to incubation with HIV-1-infected cells. After 2 hr
contact with the mucosal barrier at 37C, transcytosis was evaluated in the
basal compartment by measuring the amount of translocated p24 gag protein
and expressed as percent inhibition of transcytosis in presence of immune
CVS (at week 24) related to percentage of transcytosis in the presence of
preimmune CVS (at week 0). Error bars represent the means (±SEM) of at least
two independent experiments.
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Gp41 Vaccine Protects from Mucosal SHIV InfectionFurthermore, the transcytosis-blocking activity observed here
at the mucosal level in the CVS of the i.m.+i.n.-vaccinated
animals relied almost entirely on IgAs because IgA depletion,
but not IgG ones, totally abolished transcytosis blockade
in vitro. These findings are in agreement with previous studies
showing that gp41-dimeric IgAs and secretory IgAs could either
block HIV-1 intracellularly during transcytosis and redirect it to
the mucosal surface (Bomsel et al., 1998) or impair its mucosal
entry (Devito et al., 2000a; Alfsen et al., 2001; Broliden et al.,
2001; Miyazawa et al., 2009). IgAs have also been shown to
retro-translocate pathogens from the lamina propria into the
lumen (Corthe´sy 2007).
Taken together, our results strongly suggest that vaccine-
induced mucosal gp41-specific IgAs efficiently prevented
HIV-1 binding to the mucosal receptor galactosyl ceramide (Alf-
sen and Bomsel, 2002) or to other gp41 epitopes such as the
caveolin binding motif (Hovanessian et al., 2004), thus blocking
initial virus entry in mucosal tissues. This conclusion will have
to be strengthened and confirmed in further studies.
IgGs constitute an important fraction of vaginal antibodies,
whereas in other mucosal secretions IgAs predominate. P1-
and/or rgp41-specific ADCC activity mediated by mucosal
IgGs could also be detected in protected animals from group 3
and animals from group 2 with undetectable or transient viremia
%250 viral RNA copies/mL. In contrast, CVS from the infected
animals in group 2 showed low IgG-dependent ADCC activity
and lacked transcytosis-blocking activity. Therefore, it is
possible that transcytosis inhibition must be combined with
ADCC to block the initiation of HIV-1 infection at mucosal sites.
Indeed, previous studies have associated mucosal ADCC
activity with lower blood viremia in HIV-1-positive women (Nag
et al., 2004), and disappearance of ADCC seems to correlate276 Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc.with lower CD4+ T cell counts and progression to AIDS in men
and in the nonhuman primate model (Xiao et al., 2010 and
reviewed in Forthal and Moog, 2009). The discrepancy between
serum and mucosal IgG activities confirms the presence of
locally produced IgGs (Ogra and Ogra, 1973; Brandtzaeg
2009; Bouvet et al., 2002) and the compartmentalization of the
mucosal immune response (Bouvet and Fischetti, 1999; Mac-
pherson et al., 2008).
Knowing that the mucosal immune response is relatively short
lived, compared with blood antibodies, it will be important to
determine in future studies the duration of the protective immune
response observed here.
The most remarkable finding in this study was that mucosal
protection against a heterologous SHIV challenge in rhesus
macaques occurred in the absence of detectable neutralizing
antibodies in the serum. This is reminiscent of data on the
protection induced by injection of a panel of HIV-1-envelope-
specific IgGs (Hessell et al., 2009; 2010) and clearly challenges
the paradigm that mucosal protection requires the presence in
serum of high titers of IgGs with virus-neutralizing capacity.
Altogether, this study demonstrates that a vaccine that stimu-
lates the production of HIV-1 envelope gp41-specific antibody in
the vaginal tissue was sufficient to protect monkey from vaginal
exposure to virulent virus. This may serve toward the develop-
ment of a human vaccine against HIV-1 and acquired immuno-
deficiency syndrome and help to explain why a few individuals
who lack HIV-1-specific antibodies in the blood are able to resist
infection, even when they are repeatedly exposed to HIV-1.EXPERIMENTAL PROCEDURES
Antigens
The P1 sequence (649-683) (originally described in Alfsen and Bomsel, 2002)
derived from the HXB2 clade B HIV-1 strain and was modified to a lipid-linked
synthetic peptide having 38 amino acids with the following sequence,
SQTQQEKNEQELLELDKWASLWNWFDITNWLWYIKLSC, linked to phos-
phatidyl-ethanolamine (PE) via its C-terminal cysteine. The rgp41 protein
was derived from the amino acid sequence 540-663 of HXB2 clade B HIV-1
strain and was produced in E. coli with the following sequence, MQARQLLSG
IVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLSGGRGGSS
LEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQLLELLEHHHHC,
(italic letters correspond to the overlap region with the P1 peptide). The mole-
cule was covalently linked via a bifunctional succinate linker to PE. This rgp41
is lacking the binding motifs for the mucosal receptor galactosyl ceramide
(Alfsen and Bomsel, 2002) and the 2F5 and 4E10 motifs (Muster et al., 1993;
Stiegler et al., 2001). A deletion of 25 amino acids (593–618) was introduced
into the molecule to keep it soluble and trimeric, as well as point mutations
to greatly reduce 3D homology with the human IL-2, as previously published
(Delcroix-Geneˆte et al., 2006). The rgp41 was purified through several steps
of chromatography as described (Delcroix-Geneˆte et al., 2006), resulting in
a stable trimeric protein of 39.9 kDa.
Virosomes
Influenza virus strain A/Singapore/6/86 (H1N1) was cultivated in embryonated
hen eggs and inactivated with b-propiolactone before solubilization with
100 mM octaethylene glycol monododecyl ether in phosphate-buffered
saline-NaCl (OEG-PBS). The solubilized viral hemagglutinin (HA) and neurami-
dase (NA) were mixed with egg phosphatidylcholine (PC) and synthetic phos-
phatidylethanolamine and the antigens of interest, P1 or rgp41, previously
conjugated to PE. Detergent was removed on polystyrene beads on two
subsequent batch chromatography steps, and homogenous influenza viro-
somes, that spontaneously reconstituted, were filtered for sterilization without
further purification (Amacker et al., 2005) (Kammer et al., 2007).
Figure 5. Correlation between Peak Acute Viremia and HIV-1 Transcytosis-Blocking, ADCC, and Neutralizing Activities in Cervico-Vaginal
Secretions for All Animals
Inverse correlations (straight line) for all animals between peak acute viremia and (1) transcytosis-blockade of HIV-1 clade B (A), or HIV-1 clade C (B); (2) P1- (C) or
rgp41- (D) specific ADCC; and (3) virus neutralization (E) activities in CVS. Dotted lines represent the 95% confidence intervals. Open symbols represent placebo-
virosome-vaccinated macaques (group 1); filled symbols represent P1- and rgp41-virosome-immunized macaques. The correlation coefficients (r) and p values
are from Spearman rank analysis.
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Four weeks prior to vaccination, female Macaca mulatta monkeys of Chinese
origin were preimmunized with inactivated influenza (A/Singapore/6/86) strain,
propagated in the allantoic cavity of embryonated eggs obtained from Berna
Biotech AG and purified as described previously (Amacker et al., 2005) to
mimic the situation in human usually immune to influenza. Monkeys were
then subdivided into three groups of six animals each. Each animal received
four vaccine injections, at weeks 0, 7, 15, and 23. The placebo control group
(group 1) received intramuscular injections of IRIV (virosome alone; no HIV-1
antigen). Groups 2 and 3 received vaccine doses containing each 40 mg of
P1 peptide and 40 mg of rgp41. Group 2 received only intramuscular (i.m.)
injections, whereas group 3 received two i.m. injections at weeks 0 and 7
and then two intranasal (i.n.) injections at weeks 15 and 23. For intramuscularinjections, each dose (100 ml volume) was administered in one site (upper leg),
whereas intranasal administrations were equally distributed between the two
nostrils (50 ml per nostril) with a specific spray device (BD Medical Devices).
Animals were maintained under guidelines established by the Animal
Welfare Act and the NIH Guide for the Care and Use of Laboratory Animals,
with protocols approved by the local ethical committee.
Samples Harvesting
Blood, vaginal, and rectal washes were performed on each animal at week 4
and 0 for preimmune samples and 1 week after each vaccination event for
immune samples (weeks 1, 8, 16, and 24). Cervico-vaginal and rectal secre-
tions were obtained by gentle lavages at indicated times with 3 ml of cold
saline buffer, then added with antibiotics and protease inhibitors andImmunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc. 277
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Gp41 Vaccine Protects from Mucosal SHIV Infectioncentrifuged. Resulting supernatants were immediately aliquoted and snap
frozen in liquid nitrogen before storing at 80C (Tudor et al., 2009).
ELISA
Total antibodies were measured by standard sandwich ELISA, whereas P1- or
rgp41-specific antibodieswere evaluated by P1- or rgp41-coated direct ELISA
(Coutant et al., 2008; Tudor et al., 2009) with monkey specific-IgAs or IgGs
coupled to HRP (Rockland) as secondary antibodies.
Challenges
SHIV-SF162P3 (R5 clade B) was kindly provided by N. Miller, NIAID (NIH AIDS
Research and reference reagent program). The genome of this chimeric
simian-human immunodeficiency virus contains the env (gp120 + gp41), tat,
rev, and vpu genes from HIV-1 SF162 (Harouse et al., 2001) inserted into the
genome of the pathogenic SIVmac239. One month after vaccination, all animals
were challenged intravaginally 13 times with 2 ml of a phosphate-buffer viral
solution containing 20 TCID50 of the heterologous SHIV-SF162P3 for the first
7 challenges and 30 TCID50 for the 6 last challenges. Challenges were done
every 4–7 days.
Viremia
Blood samples were drawn over 6 months, twice a week for the first 2 weeks,
once a week for the subsequent weeks, and then once every 2 weeks, and
analyzed for plasma viral loads (viremia) with the QIAGEN QuantiTect SYBR-
Green RT-PCR kit with specific SIV gag probes (sensitivity 1000 copies/mL
blood), then repeated blindly as described (Li et al., 2009) with amore sensitive
technique. In brief, viral RNA from 0.2 ml of EDTA-anti-coagulated cell-free
plasma was directly extracted by a MagNa Pure LC robotic workstation
(Roche Molecular Biochemicals). A one-step reverse transcriptase PCR
(RT-PCR) method using the TaqMan EZ RT-PCR CORE REAGENT kit was
performed for quantification of SHIV viral RNA. Standard curves were
prepared with a series of six 10-fold dilutions of viral RNA of known concentra-
tion. The sensitivity of the assay theoretically was 100 RNA equivalents permL,
but because of volume issues, it was fixed at 200 copies/mL. Samples were
analyzed in triplicate and the number of RNA equivalents was calculated per
milliliter of plasma.
P27 Antibody Detection
Western blots with serum (diluted 1/100 for IgA, 1/200 for IgG) and cervico-
vaginal secretions (diluted 1/6) were performed in accordance with the
manufacturer’s instruction (New Lav Blot I from Bio Rad) as described (Tudor
et al., 2009) but with a monkey-specific secondary antibody coupled to HRP
(Rockland).
Functional In Vitro Assays
Inhibition of HIV-1 transcytosis (Alfsen et al., 2001; Tudor et al., 2009) and
TZM-bl (Pastori et al., 2008) (Bomsel et al., 2007), SOS (Pastori et al., 2008)
(Bomsel et al., 2007), and CD4+ T cell neutralization assays (Alfsen et al.,
2001; Tudor et al., 2009) were performed as previously described. For the
CD4+ T cell neutralization assays using the JR-CSF, R5 tropic HIV-1 molecular
clone, specific neutralization was expressed as follows:
Specific neutralization = 100 - 100 X (Infection in presence of secretion
collected at week 24/Infection in presence of secretion collected at
week 0)
For the transcytosis assays, clade B (93BR029) and C (92BR025) HIV-
1-infected PBMCs were used to inoculated HEC-1 endometrial cell lines
cultured in a polarized manner in a two-chamber system as described (Alfsen
et al., 2001; Tudor et al., 2009). CVS were tested at dilutions 1:6 and 1:12 and
the observed transcytosis-blockade was directly dependent on CVS concen-
tration (not shown). 2F5 IgA (1 mg/mL) (Shen et al., 2010) was used as positive
control and inhibited transcytosis by 95%.
Where indicated, cervico-vaginal secretions were depleted of IgAs or IgGs
by immunodepletion. In brief, biotinylated-anti-human IgA or biotinylated-
anti-human IgG (Caltag) were bound to Streptavidin-Agarose (Pierce), 10 mg/
30 ml of beads. Beads coupled with anti-human IgA or IgG antibody were
washed 3 times to removed unbound biotinylated anti-IgA or anti-IgG, after278 Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc.which 30 ml of anti-IgA- or anti-IgG-bound beads were incubated overnight
at 4C on a rotating wheel with CVS (1/6 dilution). The mixture was centrifuged
for 10 min at 10 000 g at 4C and the resulting supernatant represented the
IgA- or IgG-depleted CVS fraction. Transcytosis activity is expressed as
follows: transcytosis inhibition = 100 – 100 X (transcytosis in presence of
secretion collected at week 24/ transcytosis in presence of secretion collected
at week 0).
For the TZM-bl assays (Tudor et al., 2009), three different HIV-1 strains were
tested: SF162, the primary clade B QH0692, and the primary clade C DU172.
Virus neutralization was evaluated with the following positive controls:
2F5 IgG, which gave a 50% inhibitory concentration (IC50) of 3 mg/mL (range:
5–2 mg/mL), and an IC90 of 50 mg/mL (range 67–34 mg/mL); the TRIMAB gave
an IC50 of 0.9 mg/mL (range: 0.7–1.7 mg/mL) and an IC90 of 5 mg/mL (range:
4–6 mg/mL).
For the SOS assays (Bomsel et al., 2007) evaluated on U87.CCR5.CD4
target cells, the positive controls were 2F5 IgGwith an IC50 of 2.2 mg/mL (range
3.5–1.7 mg/mL) and IC90 of 21 mg/mL (range: 18–32 mg/mL).
Of note, SF162 and JR-CSF envelopes have 88% sequence homology, with
the differences located in the variable sequences of gp120 but not in gp41;
therefore, they are very similar in terms of gp41 sequence.
ADCC assay was performed as described (Xiao et al., 2010), with THP1
monocytic cells as effector cells and CCR5+ -NK resistant CEM lymphoid cells
(NIH AIDS reagents program) coated with either P1 or recombinant X4 tropic
gp160 as target cells. In brief, 13 106 CEM-NKR-CCR5 target cells were incu-
bated with 0.2 mMof gp160 (MN/LAI Pateur-Merieux) or 5 mMof P1 peptide for
1 hr at room temperature in a total volume of 300 ml of RPMI. Coated cells were
dually labeled with the membrane dye PKH-26 (Sigma-Aldrich) and the vital
dye CFSE (Molecular Probes, Invitrogen), then incubated for 30 min at room
temperature with the samples (3-fold dilutions) or the control antibodies, 2F5
IgG for P1-specific ADCC and 98.6 IgG for rgp41-specific ADCC, respectively,
in a 96-well microtiter plate. Effector THP1 cells were then added at a relatively
low effector/target ratio of 10:1 (Xiao et al., 2010). The reaction mixture was
incubated for 4 hr at 37C in 5% CO2 after which the cells were immediately
analyzed with a Becton Dickinson FACSCalibur flow cytometer. Data analysis
was performed with Cytomix RXP software. We determined the percentage of
ADCC cell killing by back-gating on the PKH-26high population of target cells
that lost the CFSE viability dye. For each gp41 subunit, a specific ADCC
was expressed as percent ADCC in the presence of sample collected at
week 24 subtracted by the percentage of ADCC in the presence of preimmune
sample. ADCC titers were defined as the reciprocal dilution at which the
percent ADCC killing was greater than the mean percent killing of the negative
controls plus three standard deviations. Data represent the mean of at least
two independent experiments. The positive control for P1-specific ADCC,
2F5 IgG at 1 mg/mL resulted in 40% specific cell lysis, and that for rgp41-
specific ADCC, 98.6 IgG at 100 ng/mL resulted in 60% specific cell lysis.
Both signals were entirely reversed by a 10-fold excess of non-specific IgG
(not shown), indicating that the ADCCmeasured was IgG-dependent. Further-
more, effector cells did not bind IgA or expressed the CD89 Fca receptor (not
shown).
Antibody Purification
Antibodies contained in preimmune and immune cervico-vaginal secretions
were purified on a protein G (IgG) or anion-exchange (IgA) column with an
automatic HPLC system. Eluted fractions in PBS were evaluated by ELISA
using goat anti-human IgG, IgA, or IgM as described (Donadoni et al., 2010).
MHC Genotyping
It was performed by sequence-specific PCR as described (Loffredo et al.,
2009).
Statistical Analysis
For comparing functional activities of cervico-vaginal secretions among
monkey groups, the nonparametric Kruskal-Wallis test was used. Pairwise
comparisons were performed by the nonparametric Mann-Whitney U test.
The Spearman rank correlation test was used for assessing the relationship
between viral load and transcytosis-blockade, ADCC, and neutralization,
respectively. Statistical analyses were carried out with Instat GraphPad Soft-
ware, version 5.0.
Immunity
Gp41 Vaccine Protects from Mucosal SHIV InfectionSUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.immuni.2011.01.015.
ACKNOWLEDGMENTS
We are grateful to C. Pastori (San Raffaele Scientific Institute, Milano, Italy) for
technical help, to B. Weksler (Cornell University, New York, USA) for English
editing, to Pr M. Girard for fruitful discussions and review of the manuscript,
and to C. Rochet (Mymetics, Switzerland) for constant encouragement and
support during our collaboration. L.L. and M.B. were supported by grant no.
201433 from European Commission/Seventh Framework Programme (www.
ngin.eu) and L.L. by a grant (no. 1 U19 AI062150) from NIH and grants GCE
no. 53030 and no. PP1008144 from Bill and Melinda Gates Foundation. M.B.
was supported by grants from Agence Nationale de Recherche sur le SIDA
et les He´patites (ANRS), SIDACTION-Ensemble contre le SIDA, and La Fonda-
tion pour la Recherche Me´dicale (FRM). Y.G. was supported by SIDACTION
and ANRS. R.Z. was Chief Scientific Officer and R.Z. and M.A. are share-
holders of Pevion Biotech Ltd., which provided the vaccine. S.F. is Chief Scien-
tific Officer and a member of the Executive Board of Mymetics Corp., A.C. is
Scientific Officer of Mymetics Corp. G.D. is employee of BD Medical-Pharma-
ceutical, and M.G.R. and N.M. are employees of PX’ Therapeutics .
Received: July 30, 2010
Revised: October 27, 2010
Accepted: December 10, 2010
Published online: February 10, 2011
REFERENCES
Alfsen, A., and Bomsel, M. (2002). HIV-1 gp41 envelope residues 650-685
exposed on native virus act as a lectin to bind epithelial cell galactosyl ceram-
ide. J. Biol. Chem. 277, 25649–25659.
Alfsen, A., Iniguez, P., Bouguyon, E., and Bomsel, M. (2001). Secretory IgA
specific for a conserved epitope on gp41 envelope glycoprotein inhibits
epithelial transcytosis of HIV-1. J. Immunol. 166, 6257–6265.
Amacker, M., Engler, O., Kammer, A.R., Vadrucci, S., Oberholzer, D., Cerny,
A., and Zurbriggen, R. (2005). Peptide-loaded chimeric influenza virosomes
for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 17, 695–704.
Barnett, S.W., Srivastava, I.K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A.D.,
Ferrai, M.G., Weiss, D.E., Letvin, N.L., Montefiori, D., et al. (2008). Protection
of macaques against vaginal SHIV challenge by systemic or mucosal and
systemic vaccinations with HIV-envelope. AIDS 22, 339–348.
Bomsel, M. (1997). Transcytosis of infectious human immunodeficiency virus
across a tight human epithelial cell line barrier. Nat. Med. 3, 42–47.
Bomsel, M., Heyman, M., Hocini, H., Lagaye, S., Belec, L., Dupont, C., and
Desgranges, C. (1998). Intracellular neutralization of HIV transcytosis across
tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9,
277–287.
Bomsel, M., Pastori, C., Tudor, D., Alberti, C., Garcia, S., Ferrari, D., Lazzarin,
A., and Lopalco, L. (2007). Natural mucosal antibodies reactive with first extra-
cellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
AIDS 21, 13–22.
Bouvet, J.P., and Fischetti, V.A. (1999). Diversity of antibody-mediated immu-
nity at the mucosal barrier. Infect. Immun. 67, 2687–2691.
Bouvet, J.P., Decroix, N., and Pamonsinlapatham, P. (2002). Stimulation of
local antibody production: Parenteral or mucosal vaccination? Trends
Immunol. 23, 209–213.
Brandtzaeg, P. (2009). Mucosal immunity: Induction, dissemination, and
effector functions. Scand. J. Immunol. 70, 505–515.
Broliden, K., Hinkula, J., Devito, C., Kiama, P., Kimani, J., Trabbatoni, D.,
Bwayo, J.J., Clerici, M., Plummer, F., and Kaul, R. (2001). Functional HIV-1
specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female
sex workers. Immunol. Lett. 79, 29–36.Buchbinder, S.P., Mehrotra, D.V., Duerr, A., Fitzgerald, D.W., Mogg, R., Li, D.,
Gilbert, P.B., Lama, J.R., Marmor, M., Del Rio, C., et al; Step Study Protocol
Team. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine
(the Step Study): A double-blind, randomised, placebo-controlled, test-of-
concept trial. Lancet 372, 1881–1893.
Corthe´sy, B. (2007). Roundtrip ticket for secretory IgA: Role in mucosal
homeostasis? J. Immunol. 178, 27–32.
Coutant, J., Yu, H., Cle´ment, M.J., Alfsen, A., Toma, F., Curmi, P.A., and
Bomsel, M. (2008). Both lipid environment and pH are critical for determining
physiological solution structure of 3-D-conserved epitopes of the HIV-1
gp41-MPER peptide P1. FASEB J. 22, 4338–4351.
Currier, J.R., deSouza, M., Chanbancherd, P., Bernstein, W., Birx, D.L., and
Cox, J.H. (2002). Comprehensive screening for human immunodeficiency virus
type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degen-
erate epitopes restricted by HLA-A0207 and -C(W)0304 alleles. J. Virol. 76,
4971–4986.
Delcroix-Geneˆte, D., Quan, P.L., Roger, M.G., Hazan, U., Nisole, S., and
Rousseau, C. (2006). Antiviral properties of two trimeric recombinant gp41
proteins. Retrovirology 3, 16.
Demberg, T., and Robert-Guroff, M. (2009). Mucosal immunity and protection
against HIV/SIV infection: Strategies and challenges for vaccine design. Int.
Rev. Immunol. 28, 20–48.
Devito, C., Broliden, K., Kaul, R., Svensson, L., Johansen, K., Kiama, P.,
Kimani, J., Lopalco, L., Piconi, S., Bwayo, J.J., et al. (2000a). Mucosal and
plasma IgA fromHIV-1-exposed uninfected individuals inhibit HIV-1 transcyto-
sis across human epithelial cells. J. Immunol. 165, 5170–5176.
Devito, C., Hinkula, J., Kaul, R., Lopalco, L., Bwayo, J.J., Plummer, F., Clerici,
M., and Broliden, K. (2000b). Mucosal and plasma IgA fromHIV-exposed sero-
negative individuals neutralize a primary HIV-1 isolate. AIDS 14, 1917–1920.
Devito, C., Hinkula, J., Kaul, R., Kimani, J., Kiama, P., Lopalco, L., Barass, C.,
Piconi, S., Trabattoni, D., Bwayo, J.J., et al. (2002). Cross-clade HIV-1-specific
neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed,
persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 30,
413–420.
Donadoni, C., Bisighini, C., Scotti, L., Diomede, L., Ngyen, M., Nouhin, J.,
DeSantis, L., Zambon, A., Ferrari, D., Gallotta, G., et al. (2010). Setting of
methods for analysis of mucosal antibodies in seminal and vaginal fluids of
HIV seropositive subjects from Cambodian and Italian cohorts. PLoS ONE 5,
e9920.
Forthal, D.N., and Moog, C. (2009). Fc receptor-mediated antiviral antibodies.
Curr Opin HIV AIDS 4, 388–393.
Hansen, S.G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D.C.,
Drummond, D.D., Legasse, A.W., Axthelm, M.K., Oswald, K., Trubey, C.M.,
et al. (2009). Effector memory T cell responses are associated with protection
of rhesus monkeys from mucosal simian immunodeficiency virus challenge.
Nat. Med. 15, 293–299.
Harouse, J.M., Gettie, A., Eshetu, T., Tan, R.C., Bohm, R., Blanchard, J.,
Baskin, G., and Cheng-Mayer, C. (2001). Mucosal transmission and induction
of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV
(SF162P3). J. Virol. 75, 1990–1995.
Herzog, C., Hartmann, K., Ku¨nzi, V., Ku¨rsteiner, O., Mischler, R., Lazar, H., and
Glu¨ck, R. (2009). Eleven years of Inflexal V-a virosomal adjuvanted influenza
vaccine. Vaccine 27, 4381–4387.
Hessell, A.J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D.M., Bleeker,
W.K., Parren, P.W., Marx, P.A., and Burton, D.R. (2009). Effective, low-titer
antibody protection against low-dose repeated mucosal SHIV challenge in
macaques. Nat. Med. 15, 951–954.
Hessell, A.J., Rakasz, E.G., Tehrani, D.M., Huber, M., Weisgrau, K.L.,
Landucci, G., Forthal, D.N., Koff, W.C., Poignard, P., Watkins, D.I., and
Burton, D.R. (2010). Broadly neutralizing monoclonal antibodies 2F5 and
4E10 directed against the human immunodeficiency virus type 1 gp41
membrane-proximal external region protect against mucosal challenge by
simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84, 1302–1313.Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc. 279
Immunity
Gp41 Vaccine Protects from Mucosal SHIV InfectionHladik, F., and McElrath, M.J. (2008). Setting the stage: Host invasion by HIV.
Nat. Rev. Immunol. 8, 447–457.
Hovanessian, A.G., Briand, J.P., Said, E.A., Svab, J., Ferris, S., Dali, H., Muller,
S., Desgranges, C., and Krust, B. (2004). The caveolin-1 binding domain of
HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate
against virus infection. Immunity 21, 617–627.
Kammer, A.R., Amacker, M., Rasi, S., Westerfeld, N., Gremion, C., Neuhaus,
D., and Zurbriggen, R. (2007). A new and versatile virosomal antigen delivery
system to induce cellular and humoral immune responses. Vaccine 25,
7065–7074.
Li, Y., Yang, G.B., Chen, Q.M., Liu, Q., Meng, Z.F., Geng, Y.Q., Qiao, W.T., and
Shao, Y.M. (2009). Construction and characterization of a new simian/human
immunodeficiency viruses clone carrying an env gene derived from
a CRF07_BC strain. Chin. Med. J. (Engl.) 122, 2874–2879.
Loffredo, J.T., Sidney, J., Bean, A.T., Beal, D.R., Bardet, W., Wahl, A.,
Hawkins, O.E., Piaskowski, S., Wilson, N.A., Hildebrand, W.H., et al. (2009).
Two MHC class I molecules associated with elite control of immunodeficiency
virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence
similarity. J. Immunol. 182, 7763–7775.
Macpherson, A.J., McCoy, K.D., Johansen, F.E., and Brandtzaeg, P. (2008).
The immune geography of IgA induction and function. Mucosal Immunol. 1,
11–22.
Mage´rus-Chatinet, A., Yu, H., Garcia, S., Ducloux, E., Terris, B., and Bomsel,
M. (2007). Galactosyl ceramide expressed on dendritic cells can mediate
HIV-1 transfer from monocyte derived dendritic cells to autologous T cells.
Virology 362, 67–74.
Miyazawa, M., Lopalco, L., Mazzotta, F., Lo Caputo, S., Veas, F., and Clerici,
M.; ESN Study Group. (2009). The ‘immunologic advantage’ of HIV-exposed
seronegative individuals. AIDS 23, 161–175.
Montero, M., van Houten, N.E., Wang, X., and Scott, J.K. (2008). The
membrane-proximal external region of the human immunodeficiency virus
type 1 envelope: Dominant site of antibody neutralization and target for
vaccine design. Microbiol. Mol. Biol. Rev. 72, 54–84.
Moser, C., Amacker, M., Kammer, A.R., Rasi, S., Westerfeld, N., and
Zurbriggen, R. (2007). Influenza virosomes as a combined vaccine carrier
and adjuvant system for prophylactic and therapeutic immunizations. Expert
Rev. Vaccines 6, 711–721.
Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ru¨ker,
F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human
immunodeficiency virus type 1. J. Virol. 67, 6642–6647.
Nag, P., Kim, J., Sapiega, V., Landay, A.L., Bremer, J.W., Mestecky, J.,
Reichelderfer, P., Kovacs, A., Cohn, J., Weiser, B., and Baum, L.L. (2004).
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity
have lower genital HIV-1 RNA loads. J. Infect. Dis. 190, 1970–1978.
Novitsky, V., Cao, H., Rybak, N., Gilbert, P., McLane, M.F., Gaolekwe, S.,
Peter, T., Thior, I., Ndung’u, T., Marlink, R., et al. (2002). Magnitude and
frequency of cytotoxic T-lymphocyte responses: Identification of immunodo-
minant regions of human immunodeficiency virus type 1 subtype C. J. Virol.
76, 10155–10168.
Ogra, P.L., and Ogra, S.S. (1973). Local antibody response to poliovaccine in
the human female genital tract. J. Immunol. 110, 1307–1311.
Pastori, C., Clivio, A., Diomede, L., Consonni, R., De Mori, G.M., Longhi, R.,
Colombo, G., and Lopalco, L. (2008). Two amino acid substitutions within
the first external loop of CCR5 induce human immunodeficiency virus-block-
ing antibodies in mice and chickens. J. Virol. 82, 4125–4134.280 Immunity 34, 269–280, February 25, 2011 ª2011 Elsevier Inc.Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J.,
Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al; MOPH-
TAVEG Investigators. (2009). Vaccination with ALVAC and AIDSVAX to prevent
HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220.
Serres, P.F. (2001). AIDS: An immune response against the immune system.
Role of a precise tridimensional molecular mimicry. J. Autoimmun. 16,
287–291.
Shen, R., Drelichman, E.R., Bimczok, D., Ochsenbauer, C., Kappes, J.C.,
Cannon, J.A., Tudor, D., Bomsel, M., Smythies, L.E., and Smith, P.D. (2010).
GP41-specific antibody blocks cell-free HIV type 1 transcytosis through
human rectal mucosa and model colonic epithelium. J. Immunol. 184, 3648–
3655.
Stiegler, G., Kunert, R., Purtscher, M., Wolbank, S., Voglauer, R., Steindl, F.,
and Katinger, H. (2001). A potent cross-clade neutralizing human monoclonal
antibody against a novel epitope on gp41 of human immunodeficiency virus
type 1. AIDS Res. Hum. Retroviruses 17, 1757–1765.
Sun, Z.Y., Oh, K.J., Kim, M., Yu, J., Brusic, V., Song, L., Qiao, Z., Wang, J.H.,
Wagner, G., and Reinherz, E.L. (2008). HIV-1 broadly neutralizing antibody
extracts its epitope from a kinked gp41 ectodomain region on the viral
membrane. Immunity 28, 52–63.
Tatsis, N., Lasaro, M.O., Lin, S.W., Haut, L.H., Xiang, Z.Q., Zhou, D., Dimenna,
L., Li, H., Bian, A., Abdulla, S., et al. (2009). Adenovirus vector-induced immune
responses in nonhuman primates: Responses to prime boost regimens.
J. Immunol. 182, 6587–6599.
Tudor, D., Derrien, M., Diomede, L., Drillet, A.S., Houimel, M., Moog, C.,
Reynes, J.M., Lopalco, L., and Bomsel, M. (2009). HIV-1 gp41-specific mono-
clonal mucosal IgAs derived from highly exposed but IgG-seronegative indi-
viduals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection:
An IgA gene and functional analysis. Mucosal Immunol. 2, 412–426.
Vajdy, M. (2006). Current efforts on generation of optimal immune responses
against HIV through mucosal immunisations. Drugs R D. 7, 267–288.
Vajdy, M., Singh, M., Kazzaz, J., Soenawan, E., Ugozzoli, M., Zhou, F.,
Srivastava, I., Bin, Q., Barnett, S., Donnelly, J., et al. (2004). Mucosal and
systemic anti-HIV responses in rhesus macaques following combinations of
intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 20,
1269–1281.
Wilschut, J. (2009). Influenza vaccS200ines: The virosome concept. Immunol.
Lett. 122, 118–121.
Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou,
T., Schmidt, S.D., Wu, L., Xu, L., et al. (2010). Rational design of envelope iden-
tifies broadly neutralizing human monoclonal antibodies to HIV-1. Science
329, 856–861.
Xiao, P., Zhao, J., Patterson, L.J., Brocca-Cofano, E., Venzon, D., Kozlowski,
P.A., Hidajat, R., Demberg, T., and Robert-Guroff, M. (2010). Multiple vaccine-
elicited nonneutralizing antienvelope antibody activities contribute to protec-
tive efficacy by reducing both acute and chronic viremia following simian/
human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J. Virol. 84, 7161–7173.
Yu, H., Alfsen, A., Tudor, D., and Bomsel, M. (2008). The binding of HIV-1 gp41
membrane proximal domain to its mucosal receptor, galactosyl ceramide, is
structure-dependent. Cell Calcium 43, 73–82.
Zhou, F., Goodsell, A., Uematsu, Y., and Vajdy, M. (2009). Prolonged protec-
tion against Intranasal challenge with influenza virus following systemic immu-
nization or combinations of mucosal and systemic immunizations with a heat-
labile toxin mutant. Clin. Vaccine Immunol. 16, 471–478.
